DK2919804T3 - Hurtigtvirkende insulinformulering omfattende en substitueret anionisk forbindelse - Google Patents

Hurtigtvirkende insulinformulering omfattende en substitueret anionisk forbindelse Download PDF

Info

Publication number
DK2919804T3
DK2919804T3 DK13801658.9T DK13801658T DK2919804T3 DK 2919804 T3 DK2919804 T3 DK 2919804T3 DK 13801658 T DK13801658 T DK 13801658T DK 2919804 T3 DK2919804 T3 DK 2919804T3
Authority
DK
Denmark
Prior art keywords
compound
insulin
formulation
solution
sodium
Prior art date
Application number
DK13801658.9T
Other languages
English (en)
Inventor
Olivier Soula
GéRARD SOULA
Richard Charvet
Emmanuel Dauty
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1260808A external-priority patent/FR2997952B1/fr
Priority claimed from FR1260855A external-priority patent/FR2997857B1/fr
Application filed by Adocia filed Critical Adocia
Application granted granted Critical
Publication of DK2919804T3 publication Critical patent/DK2919804T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

1. Sammensætning i vandig opløsning, omfattende insulin i hexamerisk form, i det mindste én substitueret anionisk forbindelse og en ikke-polymer polyanionisk forbindelse: - den substituerede anioniske forbindelse er valgt blandt de substituerede anioniske forbindelser i den isolerede tilstand eller i blanding bestående af et skelet dannet af et diskret antal u imellem 1 og 8 (1 < u < 8) af identiske eller forskellige saccharidenheder forbundet med identiske eller forskellige glycosid-bindinger, hvilke saccharidenheder er valgt fra gruppen bestående af hexoser, i ringform eller i reduceret åben form, kendetegnet ved, at de er substituerede med: a) i det mindste én substituent med den generelle formel I: -[Ri]a-[AA]m formel I • idet substituenterne er identiske eller forskellige, når der er i det mindste to substituenter, hvor: • radikalen -[AA]- betegner en aminosyrerest, • radikalen -Ri- er: - enten en binding og så er a = 0, og aminosyreresten -[AA] er direkte forbundet med skelettet med en funktion G, - eller en carbonkæde, og så er a = 1, med C2 til C15 eventuelt substituerede og/eller omfattende i det mindste ét heteroatom valgt blandt O, N og S og i det mindste én syrefunktion før reaktionen med aminosyren, hvilken kæde sammen med aminosyreresten -[AA] danner en amidfunktion, og er forbundet med skelettet ved hjælp af en funktion F, som resulterer af en reaktion imellem en hydroxylfunktion båret af skelettet og en funktion eller en substituent båret af forløberen for radikalen -Ri-, • F er en funktion valgt blandt funktionerne ether, ester eller carbamat, • G er en carbamatfunktion, • m er lig med 1 eller 2, • graden af substitution for saccharidenhederne, j, i -[Ri]a-[AA]m er absolut større end 0 og mindre end eller lig med 6, 0 < j 5 6, b) og eventuelt én eller flere substituenter -R'i, • substituenten -R'i er en carbonkæde med C2 til C15, eventuelt substitueret og/eller omfattende i det mindste et heteroatom valgt blandt O, N og S og i det mindste én syrefunktion i form af et salt af alkaliske kationer, hvilken kæde er forbundet med skelettet med en funktion F, som resulterer af en reaktion imellem en hydroxylfunktion eller en carboxylsyrefunktion båret af skelettet og en funktion eller en substituent båret af forløberen for substituenten -R'i, • F er en ether, ester eller carbamatfunktion, • graden af substitution for saccharidenheden, i, i -R'i, er imellem 0 og 6-j, 0 < i < 6-j og, • F og F er identiske eller forskellige, • F og G er identiske eller forskellige, • i+j ^ 6, • -R'i er identisk med eller forskellig fra -Rr, • de frie saltdannende syrefunktioner båret af substituenten -R'i er i form af salte af alkaliske kationer, • de nævnte glycosidbindinger, identiske eller forskellige, er valgt fra gruppen bestående af glycosidbindinger af type (1,1), (1,2), (1,3), (1,4) eller (1,6) 1 en alfa- eller beta-geometri.
2. Sammensætning ifølge krav 1, kendetegnet ved, at den polyanioniske forbindelse er valgt fra gruppen bestående af polycarbonsyrer eller gruppen bestående af poly-phosphorsyrer eller gruppen bestående af forbindelser af et saccharidskelet dannet af et diskret antal saccharidenheder opnået fra en disaccharidforbindelse valgt fra gruppen bestående af trehalose, maltose, lactose, saccharose, cellobiose, isomaltose, maltitol og isomaltitol eller fra gruppen af polyanioniske forbindelser bestående af et saccharidskelet dannet af et diskret antal saccharidenheder valgt fra gruppen bestående af carboxylmethylmaltotriose, carboxymethylmaltotetraose, carboxymethyl-maltopentaose, carboxymethylmaltohexaose, carboxymethylmaltoheptaose, carboxy-methylmaltooctaose og carboxymethylisomaltotriose og disses salte af Na+, K+, Ca2+ eller Mg2+.
3. Sammensætning ifølge krav 2, kendetegnet ved, at polycarbonsyren er valgt fra gruppen bestående af citronsyre, vinsyre og disses salte af Na+, K+, Ca2+ or Mg2+.
4. Sammensætning ifølge krav 2, kendetegnet ved, at den polyanioniske forbindelse bestående af saccharidskelet dannet af et diskret antal saccharidenheder er valgt fra gruppen bestående af carboxymethylmaltotriose, carboxymethylmaltotetraose, carboxymethylmaltopentaose, carboxymethylmaltohexaose, carboxymethylmalto-heptaose, carboxymethylmaltooctaose og carboxymethylisomaltotriose og disses salte af Na+, K+, Ca2+ eller Mg2+.
5. Sammensætning ifølge ethvert af de foregående krav, kendetegnet ved, at insulinet er humant insulin.
6. Sammensætning ifølge ethvert af kravene 1 til 4, kendetegnet ved, at insulinet er en insulinanalog.
7. Sammensætning ifølge krav 6, kendetegnet ved, at insulinanalogen er valgt fra gruppen omfattende insulin lispro (Humalog®), insulin aspart (Novolog®, Novorapid®) og insulin glulisin (Apidra®).
8. Sammensætning ifølge krav 7, kendetegnet ved, at insulinanalogen er insulin lispro (Humalog®).
9. Sammensætning ifølge ethvert af de foregående krav, kendetegnet ved, at masseforholdet imellem substitueret anionisk forbindelse og insulin er imellem 0,5 og 10.
10. Sammensætning ifølge ethvert af de foregående krav, kendetegnet ved, at koncentrationen af substitueret anionisk forbindelse er imellem 1,8 og 36mg/ml.
11. Farmaceutisk formulering omfattende en sammensætning ifølge ethvert af de foregående krav.
12. Farmaceutisk formulering ifølge krav 11, kendetegnet ved, at koncentrationen af insulin er imellem 240 og 3000 μΜ (40 til 500 lll/ml).
13. Anvendelse af i det mindste én substitueret anionisk forbindelse bestående af et skelet dannet af et diskret antal u imellem 1 og 8 (1 s u s 8) af identiske eller forskellige saccharidenheder forbundet med identiske eller forskellige glycosidbindinger, hvilke saccharidenheder er valgt fra gruppen bestående af hexoser, i ringform eller i reduceret åben form, hvilken forbindelse indeholder delvis substituerede carboxyl-funktionelle grupper, idet de ikke substituerede carboxylfunktionelle grupper er saltdannende, med henblik på at fremstille en farmaceutisk formulering af human insulinanalog i blanding med en polyanionisk forbindelse, som efter indgivelse muliggør en accelereret passage af insulin ind i blodet og hurtigere reduktion af glykæmi i sammenligning med en formulering, som ikke har en substitueret anionisk forbindelse og eventuelt en polyanionisk forbindelse.
14. Anvendelse ifølge krav 13, kendetegnet ved, at den substituerede anioniske forbindelse er valgt blandt de substituerede anioniske forbindelser bestående af et skelet dannet af et diskret antal u imellem 1 og 8 (1 < u < 8) af identiske eller forskellige saccharidenheder, forbundet med identiske eller forskellige glycosidbindinger, hvilke saccharidenheder er valgt fra gruppen bestående af hexoser i ringform eller i reduceret åben form, kendetegnet ved: a) at de er substituerede på statistisk måde med: > i det mindste én substituent med den generelle formel I: -[Ri]a-[AA]m formel I • substituenterne er identiske eller forskellige når der foreligger i det mindste to substituenter, hvor: • radikalen -[AA]- betegner en aminosyrerest, hvilken aminosyrerest er valgt fra gruppen bestående af phenylalanin, alfa-methyl-phenylalanin, 3,4-di-hydroxyphenylalanin, tyrosin, alfa-methyl-tyrosin, O-mehyl-tyrosin, alfa-phenylglycin, 4-hydroxyphenylglycin, 3,5-dihydroxyphenylglycin og disses salte af alkaliske kationer, hvilke derivater er i absorlut L eller D konfiguration, -[AA]- er forbundet med skelettet af molekylet ved hjælp af en binding -Ri-eller direkte forbundet med skelettet ved en funktion G, • -Ri- er: - enten en binding G, og så er a = 0, - eller en carbonkæde, og så er a = 1, med C1 til C15 eventuelt substitueret og/eller omfattende i det mindste ét heteroatom valgt blandt O, N og S og bærende i det mindste én syrefunktion før reaktionen med aminosyren, hvilken kæde sammen med aminosyrerester-[AA]- danner en amidfunktion, og er forbundet med saccaharidskelettet ved hjælp af en funktion F, som resulterer af en reaktion imellem en hydroxylfunktion båret af skelettet og en funktion båret af forløberen for Ri, • F er en ether, ester eller carbamatfunktion, • G er en ester eller carbamatfunktion, • m er lig med 1 eller 2, • graden af substitution, j, i -[Ri]a-[AA]m er absolut større end 0 og mindre end eller lig med 6, 0 < j < 6, og eventuelt ► én eller flere substituenter -R'i • -R'i er en carbonkæde med C2 til C15, eventuelt substitueret og/eller omfattende i det mindste ét heteroatom (såsom O, N og S) og bærende i det mindste én syrefunktion i form af et salt af alkaliske kationer, hvilken kæde er forbundet med saccharidskelettet ved en funktion F', som resulterer af en reaktion imellem en hydroxylfunktion båret af skelettet og en funktion båret af forløberen for-R'i, • F' er en ether, ester eller carbamatfunktion, • graden af substitution i, i -R'i, er imellem 0 og 6-j, 0 i i < 6-j, og • -R'i- er identisk med eller forskellig fra -Ri, • F og F' er identiske eller forskellige, • F' og G er identiske eller forskellige, • de frie saltdannende syrefunktioner foreligger i form af salt af alkaliske kationer, b) de nævnte glycosidiske bindinger, identiske eller forskellige, er valgt fra gruppen bestående af glycosidiske bindinger af type (1,1), (1,2), (1,3), (1,4) eller (1,6) i den alfa- eller beta-geometri, c) i + j < 6.
15. Anvendelse ifølge ethvert af kravene 13 til 14, kendetegnet ved, at den poly-anioniske forbindelse er valgt fra gruppen bestående af polycarbonsyrer eller gruppen bestående af polyphosphorsyrer eller gruppen bestående af forbindelse omfattende et saccharidskelet dannet af et diskret antal saccharidenheder opnået fra en disaccharid-forbindelse valgt fra gruppen bestående af trehalose, maltose, lactose, saccharose, cellobiose, isomaltose, maltitol og isomaltitol eller fra gruppen af polyanioniske forbindelse bestående af et saccharidskelet dannet af et diskret antal saccharidenheder valgt fra gruppen bestående af carboxymethylmaltotriose, carboxymethylmaltotetra-ose, carboxymethylmaltopentaose, carboxymethylmaltohexaose, carboxymethyl-maltoheptaose, carboxymethylmaltooctaose og carboxymethylisomaltotriose og disses salte af Na+, K+, Ca2+ eller Mg2+.
DK13801658.9T 2012-11-13 2013-11-13 Hurtigtvirkende insulinformulering omfattende en substitueret anionisk forbindelse DK2919804T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261725775P 2012-11-13 2012-11-13
FR1260808A FR2997952B1 (fr) 2012-11-13 2012-11-13 Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques
US201261726349P 2012-11-14 2012-11-14
FR1260855A FR2997857B1 (fr) 2012-11-14 2012-11-14 Formulation a action rapide d'insuline comprenant un compose anionique substitue
PCT/FR2013/052736 WO2014076423A1 (fr) 2012-11-13 2013-11-13 Formulation à action rapide d'insuline comprenant un composé anionique substitué

Publications (1)

Publication Number Publication Date
DK2919804T3 true DK2919804T3 (da) 2018-05-14

Family

ID=50728493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13801658.9T DK2919804T3 (da) 2012-11-13 2013-11-13 Hurtigtvirkende insulinformulering omfattende en substitueret anionisk forbindelse

Country Status (18)

Country Link
US (6) US9700599B2 (da)
EP (2) EP2919804B1 (da)
JP (4) JP6322642B2 (da)
KR (3) KR20150082640A (da)
CN (2) CN107952065A (da)
AU (2) AU2013346624B2 (da)
BR (1) BR112015010799B1 (da)
CA (1) CA2889552C (da)
DK (1) DK2919804T3 (da)
EA (1) EA034393B1 (da)
ES (1) ES2670969T3 (da)
HK (2) HK1213493A1 (da)
IL (2) IL238446B (da)
MX (1) MX360107B (da)
PL (1) PL2919804T3 (da)
SA (1) SA515360428B1 (da)
WO (1) WO2014076423A1 (da)
ZA (2) ZA201503293B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2741765B9 (fr) 2011-08-10 2016-09-28 Adocia Solution injectable d'au moins une insuline basale
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
BR112014016889A8 (pt) 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
AU2013346624B2 (en) * 2012-11-13 2018-08-09 Adocia Quick-acting insulin formulation including a substituted anionic compound
SG11201503598QA (en) * 2012-11-13 2015-06-29 Adocia Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
AR098168A1 (es) * 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020952B1 (fr) * 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
KR200487058Y1 (ko) 2016-08-08 2018-07-30 (주)포티스 색변 우산
JP7146363B2 (ja) 2016-09-16 2022-10-04 アサヒ飲料株式会社 容器詰果汁含有飲料
WO2018153506A1 (en) 2017-02-22 2018-08-30 Adocia Fast-acting insulin composition comprising a citric acid salt
GB201707189D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
JP6920471B2 (ja) 2017-06-01 2021-08-18 イーライ リリー アンド カンパニー 迅速に作用するインスリン組成物
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2387201A (en) 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
US2847385A (en) 1954-10-07 1958-08-12 Ohio Commw Eng Co Detergent-soil suspending composition containing carboxymethyl dextran
GB797959A (en) 1955-02-09 1958-07-09 Vitrum Apoteksvar Improvements in or relating to the preparation of insulin
JPS4722571U (da) 1971-03-09 1972-11-14
IT1053718B (it) 1973-04-04 1981-10-10 Zambeletti Spa L Metodo per prolungare l azione di farmaci attraverso la formazione di composti mcromolecolari
US4006059A (en) 1974-07-29 1977-02-01 Purdue Research Foundation Hydrophobic noncovalent binding of proteins to support materials
US4011137A (en) 1974-08-26 1977-03-08 Standard Brands Incorporated Process for producing dextrose using mixed immobilized enzymes
US4126628A (en) 1977-03-28 1978-11-21 Canadian Patents And Development Limited Acylation of amino acids
JPS53137911A (en) 1977-05-06 1978-12-01 Showa Denko Kk Preparation of n-(alpha-hydroxyalkanoyl)-peptides
SU727647A1 (ru) * 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
US4438029A (en) 1978-01-19 1984-03-20 Research Corporation Synthetic peptides
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
AU550068B2 (en) 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
EP0093551B1 (en) 1982-04-30 1991-01-16 Ajinomoto Co., Inc. Pharmaceutical composition
EP0160103B1 (en) 1983-10-26 1990-06-20 Kanebo, Ltd. Proteinous emulsifier, process for its preparation, and emulsified cosmetic preparation containing same
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
JPS6112899A (ja) 1984-06-27 1986-01-21 Hitachi Metals Ltd 異種粒子を含む金属材料の電解研磨方法
JPS61176532A (ja) 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4873322A (en) * 1986-01-24 1989-10-10 Ciba-Geigy Corporation Saccharide derivatives and processes for their manufacture
PL149145B1 (en) 1986-12-17 1990-01-31 The method of obtaining of symmetrical diamides of citric acid
DE10075034I1 (de) 1987-02-25 2001-05-23 Novo Nordisk As Insulinderivate
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
DK111489D0 (da) * 1989-03-08 1989-03-08 Novo Nordisk As Peptider
JPH03153653A (ja) 1989-11-10 1991-07-01 Kuraray Co Ltd Ｎ―（１―アルコキシカルボニルスチリル）フマルアミド酸およびその製造方法
DK0506792T3 (da) 1989-12-21 1995-10-09 Novo Nordisk As Insulinpræparat, der indeholder nikotinsyre eller nikotinamid
CA2035248A1 (en) 1990-02-06 1991-08-07 Shang-Ren Wu Vinyl carbamate compounds and detergent compositions containing them
US6027565A (en) * 1991-02-25 2000-02-22 Bugg; Charles E. Method and apparatus for crystalizing macromolecules in microgravity
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5204366A (en) 1991-06-10 1993-04-20 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US5310937A (en) 1991-06-10 1994-05-10 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents and method for the preparation thereof
NZ260933A (en) 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
JPH0782225A (ja) 1993-09-14 1995-03-28 Fuji Photo Film Co Ltd アミノ酸誘導体及びその用途
KR970007419B1 (ko) 1993-12-30 1997-05-08 한솔제지 주식회사 승화형 열전사 기록용 색소
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5807315A (en) 1995-11-13 1998-09-15 Minimed, Inc. Methods and devices for the delivery of monomeric proteins
JP2757252B2 (ja) 1995-11-27 1998-05-25 工業技術院長 重合性糖エステル及びその製造方法
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JP3991240B2 (ja) * 1997-03-10 2007-10-17 東洋紡績株式会社 スフィンゴ糖脂質合成用高分子プライマーおよびその用途
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002535287A (ja) 1999-01-26 2002-10-22 イーライ・リリー・アンド・カンパニー 単分散性６量体のアシル化されたインスリンアナログ製剤
WO2000064845A1 (fr) 1999-04-22 2000-11-02 Sankyo Company, Limited Cetoamides porteurs de resine et leur procede de preparation
WO2001035943A2 (en) 1999-11-15 2001-05-25 Gangal Hanamaraddi T Dextrose and insulin fluid formulation for intravenous infusion
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
JP5089845B2 (ja) 2000-09-06 2012-12-05 エミスフェアー・テクノロジーズ・インク シアノフェノキシカルボン酸化合物および活性薬剤送達用組成物
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
GB0119665D0 (en) 2001-08-10 2001-10-03 Isis Innovation Conjugates
EP2272501B1 (en) 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
AU2003236201A1 (en) 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2004050620A2 (en) 2002-12-03 2004-06-17 Enobia Pharma Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
JP2006516262A (ja) 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
JP4748791B2 (ja) 2003-02-24 2011-08-17 独立行政法人科学技術振興機構 蛍光性ランタニド錯体
TW200529869A (en) 2003-03-04 2005-09-16 Technology Dev Company Ltd Delivery system for drug and cell therapy
ATE373444T1 (de) 2003-04-22 2007-10-15 Biodel Inc Kissen zur hautreinigung und hautbefeuchtung
WO2004111259A2 (en) 2003-06-12 2004-12-23 Perkinelmer Las, Inc. Hydrolytic substrates for an analyte-dependent enzyme activation system
PT103003A (pt) 2003-08-04 2005-02-28 Inst Superior Tecnico Novos inibidores de metalo-enzimas com potencial aplicacao em medicina
CN100372862C (zh) 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
CA2553392A1 (en) 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
US20080085298A1 (en) 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080096800A1 (en) 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
ATE433746T1 (de) 2004-03-12 2009-07-15 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
DE602005020269D1 (de) 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
FR2914305B1 (fr) 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
US20070244467A1 (en) 2005-09-28 2007-10-18 Biodel, Inc., State Of Incorporation Delaware Self-Filling Two Chamber Injectable Device
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP2007177185A (ja) 2005-12-28 2007-07-12 Dai Ichi Kogyo Seiyaku Co Ltd 乳化重合用乳化剤、ポリマーエマルションの製造方法及びポリマーエマルション
JP2007177182A (ja) 2005-12-28 2007-07-12 Dai Ichi Kogyo Seiyaku Co Ltd 乳化重合用乳化剤、ポリマーエマルションの製造方法及びポリマーエマルション
IL172896A0 (en) 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2007098058A2 (en) 2006-02-16 2007-08-30 Biodel, Inc. Device for sublingual drug delivery using iontophoresis
US7410045B2 (en) 2006-03-06 2008-08-12 Meadwestvaco Packaging Systems, Llc Offset overhead plunger
WO2007116143A1 (fr) 2006-04-07 2007-10-18 Adocia Polysaccharides bifonctionnalises
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20120041079A1 (en) 2006-09-26 2012-02-16 Adocia Dextran functionalized by hydrophobic amino acids
WO2008062466A2 (en) 2006-10-13 2008-05-29 Reliance Life Sciences Pvt. Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
FR2919188B1 (fr) 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
EP2178909B1 (en) * 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
CN101951957A (zh) 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
FR2927900B1 (fr) 2008-02-27 2010-09-17 Clariant Specialty Fine Chem Procede de preparation d'alpha-aminoacetals optiquement actifs.
JP2009215207A (ja) 2008-03-10 2009-09-24 Hokkaido Univ Ｏ−マンノース型糖鎖結合アミノ酸及びそれを用いた糖ペプチドの製造方法
GB2458473A (en) * 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US20090291114A1 (en) 2008-04-14 2009-11-26 Adocia Osteogenic composition comprising a growth factor/amphiphilic polymer complex, a soluble cation salt and an organic support
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8470574B2 (en) 2008-05-07 2013-06-25 Toyo Boseki Kabushiki Kaisha L-succinylaminoacylase and process for producing L-amino acid using it
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
FR2934999B1 (fr) 2008-08-13 2011-07-29 Adocia Polysaccharides fonctionnalises par des derives du tryptophane
WO2010028055A1 (en) 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
BRPI0913684A2 (pt) 2008-09-26 2015-10-20 Adocia complexo composto por um polissacarídeo substituído por um triptofano ou um derivado de triptofano a partir de uma proteína ligadora à heparina, composição farmacêutica e seus usos
FR2940802A1 (fr) 2008-10-10 2010-07-09 Adocia Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide.
US8597632B2 (en) * 2008-10-03 2013-12-03 Glycan Biosciences Llc Anionic oligosaccharide conjugates
FR2936800B1 (fr) * 2008-10-06 2010-12-31 Adocia Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe
US8759322B2 (en) 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
FR2948573B1 (fr) 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques
US8728771B2 (en) 2008-12-11 2014-05-20 Toyo Boseki Kabushiki Kaisha L-succinylaminoacylase and process for producing L-amino acid using it
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US20120094902A1 (en) * 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
FR2980796B1 (fr) 2011-09-30 2014-07-04 Adocia Oligosaccharides fonctionnalises
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
JP2010235477A (ja) * 2009-03-30 2010-10-21 Asahi Kasei Chemicals Corp 糖エステル化合物
CN101920019B (zh) 2009-06-10 2012-06-06 浙江中医药大学 亲水性聚合物-葛根素特异性缀合的非溶血性缀合物
ES2440289T3 (es) 2009-06-26 2014-01-28 Novo Nordisk A/S Preparación que comprende insulina, nicotinamida y arginina
TWI513462B (zh) 2009-11-13 2015-12-21 Toray Industries 糖尿病之治療或預防藥
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
MX2012008389A (es) * 2010-01-22 2012-08-15 Dupont Nutrition Biosci Aps Metodos para producir compuestos glicolipidos sustituidos con aminas.
WO2011098962A2 (fr) 2010-02-09 2011-08-18 Adocia Polysaccharides anioniques fonctionnalisés par au moins deux groupements hydrophobes portés par un spacer au moins trivalent
FR2958647B1 (fr) 2010-04-08 2013-08-23 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
JP2011207798A (ja) * 2010-03-29 2011-10-20 Sumitomo Chemical Co Ltd 樹脂用の加工安定化剤、該加工安定化剤を含む樹脂組成物、および樹脂の加工安定性を向上させる方法
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
US8476238B2 (en) 2010-06-29 2013-07-02 Mycomagic Biotechnology Co., Ltd. Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
WO2012002450A1 (ja) 2010-06-30 2012-01-05 積水メディカル株式会社 Ｄ－サクシニラーゼ、およびこれを用いたｄ－アミノ酸の製造方法
WO2012006283A1 (en) 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
JP2012125162A (ja) 2010-12-13 2012-07-05 Toyama Prefecture チューリッポシド類をチューリッパリン類に変換する酵素活性を有するタンパク質及びそれをコードするポリヌクレオチド
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
WO2012124513A1 (ja) 2011-03-14 2012-09-20 東洋紡績株式会社 Ｎ－サクシニル－ｄｌ－アミノ酸に対する向上されたｄ体選択性を有する改変型ｄ－サクシニラーゼ
EP2828297A1 (fr) * 2011-05-10 2015-01-28 Adocia Oligosaccharides fonctionnalisés
US20120295833A1 (en) 2011-05-10 2012-11-22 Adocia Polysaccharides having an adjustable degree of functionalization
JP6020447B2 (ja) 2011-05-18 2016-11-02 三菱瓦斯化学株式会社 酸素吸収剤
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
BR112013032265A2 (pt) 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
EP2741765B9 (fr) 2011-08-10 2016-09-28 Adocia Solution injectable d'au moins une insuline basale
EP2773675B1 (fr) * 2011-11-02 2023-03-01 Adocia Formulation à action rapide d'insuline comprenant un oligosaccharide
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP6067746B2 (ja) 2011-12-30 2017-01-25 ハロザイム インコーポレイテッド Ｐｈ２０ポリペプチド変異体、その製剤および使用
BR112014016889A8 (pt) 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
AU2013346624B2 (en) 2012-11-13 2018-08-09 Adocia Quick-acting insulin formulation including a substituted anionic compound
SG11201503598QA (en) * 2012-11-13 2015-06-29 Adocia Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
US20140336610A1 (en) 2013-04-09 2014-11-13 Biodel, Inc. Methods and devices for point of use mixing of pharmaceutical formulations
JP2015010075A (ja) 2013-07-01 2015-01-19 学校法人神戸学院 γ−グルタミルシクロトランスフェラーゼ阻害剤
WO2015031709A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations comprising a peptide and a vasodilatory agent
BR112016016290A2 (pt) 2014-01-13 2017-10-03 Thermalin Diabetes Llc Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
FR3020952B1 (fr) 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
WO2018153506A1 (en) 2017-02-22 2018-08-30 Adocia Fast-acting insulin composition comprising a citric acid salt

Also Published As

Publication number Publication date
ZA201503293B (en) 2022-05-25
BR112015010799B1 (pt) 2023-01-17
KR20200084927A (ko) 2020-07-13
BR112015010799A2 (da) 2017-08-15
IL274077A (en) 2020-06-30
US20200237877A1 (en) 2020-07-30
PL2919804T3 (pl) 2018-07-31
HK1252137A1 (zh) 2019-05-17
WO2014076423A1 (fr) 2014-05-22
KR102205512B1 (ko) 2021-01-20
US20200113976A1 (en) 2020-04-16
US10881716B2 (en) 2021-01-05
US20140142034A1 (en) 2014-05-22
EP3332810B1 (fr) 2021-01-13
AU2018208773B2 (en) 2020-08-06
JP2015537024A (ja) 2015-12-24
US20140378373A2 (en) 2014-12-25
CN104902922A (zh) 2015-09-09
AU2018208773A1 (en) 2018-08-16
EP2919804B1 (fr) 2018-01-31
US10646551B2 (en) 2020-05-12
EP3332810A1 (fr) 2018-06-13
ES2670969T3 (es) 2018-06-04
CN104902922B (zh) 2017-12-12
AU2013346624A1 (en) 2015-05-14
US20210060133A1 (en) 2021-03-04
US11324808B2 (en) 2022-05-10
US20170368146A1 (en) 2017-12-28
ZA202003132B (en) 2023-04-26
US10583175B2 (en) 2020-03-10
JP2019142955A (ja) 2019-08-29
KR20150082640A (ko) 2015-07-15
CA2889552A1 (fr) 2014-05-22
CN107952065A (zh) 2018-04-24
AU2013346624B2 (en) 2018-08-09
JP7332139B2 (ja) 2023-08-23
EA201590944A1 (ru) 2016-05-31
US20170143835A1 (en) 2017-05-25
HK1213493A1 (zh) 2016-07-08
IL238446A0 (en) 2015-06-30
IL238446B (en) 2020-04-30
MX2015005786A (es) 2015-09-23
KR102367083B1 (ko) 2022-02-24
JP2023099873A (ja) 2023-07-13
EA034393B1 (ru) 2020-02-03
CA2889552C (fr) 2023-10-10
EP2919804A1 (fr) 2015-09-23
JP6322642B2 (ja) 2018-05-09
MX360107B (es) 2018-10-23
US9700599B2 (en) 2017-07-11
KR20210008934A (ko) 2021-01-25
JP2018021075A (ja) 2018-02-08
SA515360428B1 (ar) 2017-12-05

Similar Documents

Publication Publication Date Title
US10646551B2 (en) Rapid-acting insulin formulation comprising a substituted anionic compound
US9492467B2 (en) Rapid-acting insulin formulation comprising an oligosaccharide
KR20110137815A (ko) 속효성 인슐린 제형
US20120094902A1 (en) Fast-acting insulin formulation
EP2773675A1 (fr) Formulation à action rapide d&#39;insuline comprenant un oligosaccharide
US20160015814A1 (en) Fast-acting insulin formulation comprising a substituted anionic compound and a polyanionic compound
US20170136097A1 (en) Rapid-acting insulin composition comprising a substituted citrate
FR2997857A1 (fr) Formulation a action rapide d&#39;insuline comprenant un compose anionique substitue